-
Something wrong with this record ?
Plasma asprosin, CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease
H. H. Wang, W. Y. Luo, M. Lin, X. J. Li, G. D. Xiang, S. D Triganti
Language English Country Czech Republic
Document type Comparative Study, Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Angiopoietin-Like Protein 4 MeSH
- Atherosclerosis diagnostic imaging etiology MeSH
- Biomarkers blood MeSH
- Crohn Disease blood complications diagnosis MeSH
- Adult MeSH
- Extracellular Matrix Proteins blood MeSH
- Fibrillin-1 blood MeSH
- Risk Assessment MeSH
- Insulin Resistance * MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Prognosis MeSH
- Heart Disease Risk Factors MeSH
- Case-Control Studies MeSH
- Colitis, Ulcerative blood complications diagnosis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
Asprosin, coiled-coil domain-containing 80(CCDC80) and angiopoietin-like4(ANGPTL4) are newly discovered adipocytokine that affects glucose tolerance, insulin resistance and cardiovascular diseases. The goal of this study was to investigate if a relationship exists among asprosin, CCDC80 and ANGPTL4 and inflammatory bowel disease (IBD). Fifty subjects with newly diagnosed IBD and fifty healthy individuals were enrolled. Patients were treated with standard therapies for 3 months. Plasma asprosin, CCDC80 and ANGPTL4 levels were measured with enzyme-linked immunosorbent assay. High resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia (flow-mediated dilation, FMD) and after sublingual glyceryltrinitrate.Compare with healthy individuals, plasma CCDC80,erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels and homeostasis modelassessment of insulin resistance (HOMA-IR) were significantly higher (p < 0.05, respectively), whereas plasma asprosin,ANGPTL4 levels and FMD were significantly lower inboth UC and CD patients(p <0.05). Plasma CCDC80 levels were significantly higher in patients with CD (p<0.05), while plasma asprosin and ANGPTL4 levels were lower (p<0.05) as compared with those in patients with UC. Standard therapies increased plasma asprosin, ANGPTL4 levels and FMD in both UC and CD (p<0.05),UC and CD patientswhile decreased plasma CCDC80, ESR, CRP levels and HOMA-IR (p<0.05). The changes in HOMA-IR and FMD were correlated with the changes in plasma asprosin, CCDC80 and ANGPTL4 levels over the study period (p<0.05). Plasma asprosin, CCDC80 and ANGPTL4 levels may be applied as a significant marker for early stage of insulin resistance and atherosclerosis in IBD, especially of CD.
Department of Endocrinology Tungwah Hospital of Sun Yat Sen University Dongguan China
Department of Endocrinology Wuhan General Hospital of Guangzhou Command Wuhan China
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22000836
- 003
- CZ-PrNML
- 005
- 20220225103449.0
- 007
- ta
- 008
- 220106s2021 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934547 $2 doi
- 035 __
- $a (PubMed)33676388
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Wang, Hao-Hua $u Department of Endocrinology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, China
- 245 10
- $a Plasma asprosin, CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease / $c H. H. Wang, W. Y. Luo, M. Lin, X. J. Li, G. D. Xiang, S. D Triganti
- 504 __
- $a Literatura
- 520 9_
- $a Asprosin, coiled-coil domain-containing 80(CCDC80) and angiopoietin-like4(ANGPTL4) are newly discovered adipocytokine that affects glucose tolerance, insulin resistance and cardiovascular diseases. The goal of this study was to investigate if a relationship exists among asprosin, CCDC80 and ANGPTL4 and inflammatory bowel disease (IBD). Fifty subjects with newly diagnosed IBD and fifty healthy individuals were enrolled. Patients were treated with standard therapies for 3 months. Plasma asprosin, CCDC80 and ANGPTL4 levels were measured with enzyme-linked immunosorbent assay. High resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia (flow-mediated dilation, FMD) and after sublingual glyceryltrinitrate.Compare with healthy individuals, plasma CCDC80,erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels and homeostasis modelassessment of insulin resistance (HOMA-IR) were significantly higher (p < 0.05, respectively), whereas plasma asprosin,ANGPTL4 levels and FMD were significantly lower inboth UC and CD patients(p <0.05). Plasma CCDC80 levels were significantly higher in patients with CD (p<0.05), while plasma asprosin and ANGPTL4 levels were lower (p<0.05) as compared with those in patients with UC. Standard therapies increased plasma asprosin, ANGPTL4 levels and FMD in both UC and CD (p<0.05),UC and CD patientswhile decreased plasma CCDC80, ESR, CRP levels and HOMA-IR (p<0.05). The changes in HOMA-IR and FMD were correlated with the changes in plasma asprosin, CCDC80 and ANGPTL4 levels over the study period (p<0.05). Plasma asprosin, CCDC80 and ANGPTL4 levels may be applied as a significant marker for early stage of insulin resistance and atherosclerosis in IBD, especially of CD.
- 650 _2
- $a dospělí $7 D000328
- 650 _7
- $a angiopoetinu podobný protein 4 $7 D000075803 $2 czmesh
- 650 _2
- $a ateroskleróza $x diagnostické zobrazování $x etiologie $7 D050197
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ulcerózní kolitida $x krev $x komplikace $x diagnóza $7 D003093
- 650 _2
- $a Crohnova nemoc $x krev $x komplikace $x diagnóza $7 D003424
- 650 _2
- $a extracelulární matrix - proteiny $x krev $7 D016326
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibrilin 1 $x krev $7 D000071838
- 650 _2
- $a rizikové faktory kardiovaskulárních chorob $7 D000082742
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a inzulinová rezistence $7 D007333
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Luo, Wan-Ying $u Department of Endocrinology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, China
- 700 1_
- $a Lin, Min $u Department of Endocrinology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, China
- 700 1_
- $a Li, Xiao-Jing $u Department of Endocrinology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, China
- 700 1_
- $a Xiang, Guang-Da $u Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, China
- 700 1_
- $a D. Triganti, Silvia $u University of Maryland, Baltimore, USA
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 2 (2021), s. 203-211
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33676388 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20220106 $b ABA008
- 991 __
- $a 20220225103441 $b ABA008
- 999 __
- $a ok $b bmc $g 1755667 $s 1151982
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 70 $c 2 $d 203-211 $e 20210308 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20220106